ACURATE neo2 and Prime aortic valve systems

Search documents
Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
Benzingaยท 2025-05-28 19:40
Core Viewpoint - Boston Scientific Corporation has decided to cease global sales and regulatory efforts for its ACURATE neo2 and Prime aortic valve systems due to increased demands from health authorities making the process too costly [1][2][3] Group 1: Company Actions - The company has halted its pursuit of FDA approval for the ACURATE valve systems [2][3] - Boston Scientific based its decision on recent discussions with regulators, noting that the additional resources required to meet new clinical and regulatory demands are prohibitive [3] Group 2: Financial Outlook - Despite the setback, Boston Scientific remains confident in its broader portfolio and is on track to meet its financial targets for the quarter and full year [2] - The company has not reaffirmed its GAAP EPS guidance for the second quarter and full year 2025, but estimates 2025 GAAP earnings of $1.86-$1.93 per share and second-quarter earnings of $0.45 to $0.47 per share [4] - Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, adjusting previous guidance [5]